Drug Profile
Research programme: immunoproteasome inhibitors - Onyx Pharmaceuticals
Alternative Names: ONX 0914; ONYX 0914; PR-957Latest Information Update: 03 Feb 2023
Price :
$50
*
At a glance
- Originator Proteolix
- Developer Onyx Pharmaceuticals
- Class Epoxy compounds; Ketones; Peptides; Small molecules
- Mechanism of Action Proteasome inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haemophagocytic lymphohistiocytosis
- No development reported Autoimmune disorders; Haematological malignancies
Most Recent Events
- 17 Jan 2023 Preclinical trials in Haemophagocytic lymphohistiocytosis in USA (unspecified route) before January 2023
- 10 Dec 2022 Pharmacodynamics data from preclinical studies in Hemophagocytic lymphohistiocytosis presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2022)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA